» Articles » PMID: 38975893

DrugMetric: Quantitative Drug-likeness Scoring Based on Chemical Space Distance

Overview
Journal Brief Bioinform
Specialty Biology
Date 2024 Jul 8
PMID 38975893
Authors
Affiliations
Soon will be listed here.
Abstract

The process of drug discovery is widely known to be lengthy and resource-intensive. Artificial Intelligence approaches bring hope for accelerating the identification of molecules with the necessary properties for drug development. Drug-likeness assessment is crucial for the virtual screening of candidate drugs. However, traditional methods like Quantitative Estimation of Drug-likeness (QED) struggle to distinguish between drug and non-drug molecules accurately. Additionally, some deep learning-based binary classification models heavily rely on selecting training negative sets. To address these challenges, we introduce a novel unsupervised learning framework called DrugMetric, an innovative framework for quantitatively assessing drug-likeness based on the chemical space distance. DrugMetric blends the powerful learning ability of variational autoencoders with the discriminative ability of the Gaussian Mixture Model. This synergy enables DrugMetric to identify significant differences in drug-likeness across different datasets effectively. Moreover, DrugMetric incorporates principles of ensemble learning to enhance its predictive capabilities. Upon testing over a variety of tasks and datasets, DrugMetric consistently showcases superior scoring and classification performance. It excels in quantifying drug-likeness and accurately distinguishing candidate drugs from non-drugs, surpassing traditional methods including QED. This work highlights DrugMetric as a practical tool for drug-likeness scoring, facilitating the acceleration of virtual drug screening, and has potential applications in other biochemical fields.

Citing Articles

Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification.

Gomaa M, Alturki M, Tawfeeq N, Hussein D, Pottoo F, Al Khzem A Pharmaceutics. 2025; 16(12.

PMID: 39771585 PMC: 11679513. DOI: 10.3390/pharmaceutics16121607.


Family Malvaceae: a potential source of secondary metabolites with chemopreventive and anticancer activities supported with pharmacokinetic and pharmacodynamic profiles.

Sameh S, Elissawy A, Al-Sayed E, M Labib R, Chang H, Yu S Front Pharmacol. 2024; 15:1465055.

PMID: 39478959 PMC: 11521888. DOI: 10.3389/fphar.2024.1465055.

References
1.
Zhou Z, Kearnes S, Li L, Zare R, Riley P . Optimization of Molecules via Deep Reinforcement Learning. Sci Rep. 2019; 9(1):10752. PMC: 6656766. DOI: 10.1038/s41598-019-47148-x. View

2.
Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade R . Artificial intelligence in drug discovery and development. Drug Discov Today. 2020; 26(1):80-93. PMC: 7577280. DOI: 10.1016/j.drudis.2020.10.010. View

3.
Olivecrona M, Blaschke T, Engkvist O, Chen H . Molecular de-novo design through deep reinforcement learning. J Cheminform. 2017; 9(1):48. PMC: 5583141. DOI: 10.1186/s13321-017-0235-x. View

4.
Jiang D, Wu Z, Hsieh C, Chen G, Liao B, Wang Z . Could graph neural networks learn better molecular representation for drug discovery? A comparison study of descriptor-based and graph-based models. J Cheminform. 2021; 13(1):12. PMC: 7888189. DOI: 10.1186/s13321-020-00479-8. View

5.
Cai C, Lin H, Wang H, Xu Y, Ouyang Q, Lai L . miDruglikeness: Subdivisional Drug-Likeness Prediction Models Using Active Ensemble Learning Strategies. Biomolecules. 2023; 13(1). PMC: 9855665. DOI: 10.3390/biom13010029. View